Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

Core Insights - Sight Sciences, Inc. announced new findings from the ROMEO study, indicating that the OMNI Surgical System is effective in treating advanced glaucoma patients, challenging previous beliefs about treatment efficacy in severe cases [1][2][3] Group 1: Study Findings - The analysis showed that ab interno canaloplasty combined with trabeculotomy using OMNI effectively lowered intraocular pressure (IOP) and reduced medication usage across all severity levels of glaucoma [2][5] - 70% of eyes experienced a reduction in IOP at 12 months, with 92% achieving IOP levels of 18 mmHg or less [5] - The mean IOP at month 12 ranged between 14 mmHg and 16 mmHg, consistent across different severity groups [5] - A significant percentage of patients (50% to 69%) showed a reduction of at least one medication, indicating the treatment's effectiveness [5] - Regression analysis indicated no significant relationship between month 12 IOP and visual field loss, suggesting consistent treatment outcomes regardless of disease severity [5] Group 2: Study Design and Demographics - The ROMEO study was a retrospective case series approved by an Institutional Review Board, conducted at eleven ophthalmology practices in the U.S. [3] - The majority of participants (95%) had primary open-angle glaucoma and underwent the implant-free OMNI procedure, which is FDA-cleared for canaloplasty and trabeculotomy [3][4] Group 3: Company Vision and Technology - Sight Sciences aims to transform eyecare through innovative, minimally invasive technologies that address the underlying causes of prevalent eye diseases [8] - The OMNI Surgical System is indicated for reducing IOP in adult patients with primary open-angle glaucoma and is CE marked for additional procedures [8] - The company is committed to providing effective treatment options for glaucoma patients at all disease stages, reinforcing its dedication to advancing eyecare technology [6]